TScan Therapeutics (TCRX) Change in Accured Expenses (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Change in Accured Expenses data on file, last reported at $904000.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 116.7% year-over-year to $904000.0 in Q1 2026; TTM through Mar 2026 was -$908000.0, a 226.11% decrease from a year earlier, with the FY2025 full-year figure at -$7.2 million, down 259.44% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $904000.0, up from -$3.4 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for TCRX reached as high as $3.7 million in Q4 2024 and fell as low as -$5.4 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $164411.8 across 5 years, with a median of $783000.0 in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 179.33% in 2024 and fell as far as 317.37% in 2024.
• Year by year, Change in Accured Expenses stood at $1.3 million in 2022, then retreated by 0.91% to $1.3 million in 2023, then jumped by 179.33% to $3.7 million in 2024, then plunged by 192.16% to -$3.4 million in 2025, then surged by 126.79% to $904000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $904000.0 in Q1 2026, -$3.4 million in Q4 2025, and -$1.1 million in Q3 2025.